The future of medicine
What We Do
Viro-Gen develops immunotherapy conjugates that offer precision pathogen clearance with negligible side effects.
Technology Thesis
In a mice study at a European CRO, Viro-Gen demonstrated the therapeutic characteristics of an immune system fibroblast protein. Our team of Virologists achieved viral clearance in HIV infected mice using this protein. Viro-Gen has used this endogenous protein to develop a broadly immunising therapeutic candidate, Vimmodulan ®, for clinical development.
Our platform pipeline is leveraging small molecule conjugates to deliver targeted use of this fibroblast protein for solid tumours. Our VG101 platform offers promise for a wide range of solid tumour therapeutics.
Technology Thesis
In a mice study at a European CRO, Viro-Gen demonstrated the therapeutic characteristics of an immune system fibroblast protein. Our team of Virologists achieved viral clearance in HIV infected mice using this protein. Viro-Gen has used this endogenous protein to develop a broadly immunising therapeutic candidate, Vimmodulan ®, for clinical development.
Our platform pipeline is leveraging small molecule conjugates to deliver targeted use of this fibroblast protein for solid tumours. Our VG101 platform offers promise for a wide range of solid tumour therapeutics.
Isotekh
We refer to our Vimmodulan ® platform for broad Immune System Optimization as an ISOTEKH
Isotekh
We refer to our Vimmodulan ® platform for broad Immune System Optimization as an ISOTEKH
Our Team
Our team is comprised of virologists, pharmacologists, professors and investment professionals who are driving Viro-Gen’s vision and mission to transform treatment approaches in a wide range of communicable and non-communicable diseases
Our Team
Our team is comprised of virologists, pharmacologists, professors and investment professionals who are driving Viro-Gen’s vision and mission to transform treatment approaches in a wide range of communicable and non-communicable diseases
We refer to our VG101 targeted conjugate platform for Targeted Immunotherapy as a TARGOTEKH
We refer to our VG101 targeted conjugate platform for Targeted Immunotherapy as a TARGOTEKH
Our Address
PMA House, Block B, Ground Floor,
Tijger Vallei Office Park, Silver Lakes Road,
Silver Lakes, Pretoria, 0081
Contact Us
Tel No: +27 (0)87 092 5148
Email: info@viro-gen.com